Skip to main
NUVL
NUVL logo

Nuvalent (NUVL) Stock Forecast & Price Target

Nuvalent (NUVL) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Nuvalent Inc's robust clinical data for its product candidates indicates strong efficacy and a favorable tolerability profile, particularly in a large safety population of 432 patients. The company's therapies, especially NVL-520 and NVL-655, demonstrate promising durable central nervous system (CNS) activity, with landmark overall response rates (ORRs) at 96% for both 6- and 12-month durations. These factors suggest a significant potential for market uptake, particularly in the ROS1-positive non-small cell lung cancer segment upon the anticipated approval of zidesamtinib in 2026.

Bears say

Nuvalent Inc faces significant near-term risks that contribute to a negative outlook on its stock, primarily linked to the potential for poorer-than-expected clinical results for its key product candidates, NVL-520 and NVL-655. Such adverse outcomes could necessitate downward revisions in market penetration projections, lead to higher discount rates, and extend the anticipated timelines for potential drug approvals. Additionally, the company confronts competitive threats from superior products and regulatory challenges, particularly regarding its ability to secure favorable reimbursement terms upon commercialization.

Nuvalent (NUVL) has been analyzed by 9 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nuvalent and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nuvalent (NUVL) Forecast

Analysts have given Nuvalent (NUVL) a Buy based on their latest research and market trends.

According to 9 analysts, Nuvalent (NUVL) has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $118.89, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $118.89, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nuvalent (NUVL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.